New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Statin-associated muscle symptoms (SAMS) are the most common toxicity of statins, as shown by manifestations of myalgia, myopathy, myositis with increased creatine kinase (CK), or rhabdomyolysis (Ward et al., 2019), and SAMS risk appears to link with systemic exposure to higher doses of statins (Armitage et al., 2010)
Advances in Nutrition
Funding Research reported in this publication was supported by R01 DK115534 and K24 HL155861 (PI: Dr
PMID: 24846705
Some patients find it helpful to use a mirror or ask a family member, carer, or healthcare professional to assist with arm injections, particularly when first learning the technique
